The guideline article “Management of hypersensitivity to platinumand taxane-based chemotherapy: cepo review and clinical recommendations” in this journal for the management of hypersensitivity reactions (hsr) to this group of chemotherapy agents is useful in clinical practice1. Administration of H1 and H2 blockers in addition to steroids and reduced infusion rates are important tools for a reac...

BACKGROUND The majority of women with ovarian cancer develop recurrent disease. For patients with a platinum-free interval of >6 months, platinum-based chemotherapy is a treatment of choice. The benefit of platinum-based combination chemotherapy in randomized trials varies, and a meta-analysis was carried out to gain more secure information on the size of the benefit of this treatment. MATERI...

We have examined a panel of 12 unrelated human ovarian cancer cell lines derived from patients who were either untreated or treated with platinum-based chemotherapy to determine whether a relationship is present between cisplatin sensitivity and: (a) cellular platinum accumulation; (b) glutathione levels; (c) platinum-DNA adduct formation; (d) platinum-DNA adduct removal; and (e) platinum-DNA d...

The electrooxidation of formic acid on Pt and other noble metal electrodes proceeds through a dual-path mechanism, composed of a direct path and an indirect path through adsorbed carbon monoxide, a poisoning intermediate. Adsorbed formate had been identified as the reactive intermediate in the direct path. Here we show that actually it is also the intermediate in the indirect path and is, hence...

OBJECTIVES To review the available systemic treatments for women with recurrent ovarian cancer. METHODS A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer...

OBJECTIVE The objective of this study was to compare hospital costs per treatment cycle (HCTC) for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer (AdvNS-NSCLC) in Chinese patients. METHODS Patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC from 2010 t...

The metal resistant bacterium Cupriavidus metallidurans CH34, challenged with aqueous platinous and platinic chloride, rapidly immobilized platinum. XANES/EXAFS analysis of these reaction systems demonstrated that platinum binding shifted from chloride to carboxyl functional groups within the bacteria. Pt(IV) was more toxic than Pt(II), presumably due to the oxidative stress imparted by the pla...

Ovarian cancer is characterized by an increase in cellular energy metabolism, which is predominantly satisfied by glucose and glutamine. Targeting metabolic pathways is an attractive approach to enhance the therapeutic effectiveness and to potentially overcome drug resistance in ovarian cancer. In platinum-sensitive ovarian cancer cell lines the metabolism of both, glucose and glutamine was ini...

a-Amino Acid Esters, Peptide Esters, Platinum(IV) Complexes, "N NMR Spectra, Pt NMR Spectra The platinum(IV) complexes PtX4L2 (X = Cl, Br; 2 X = oxalate; L = glyOEt, glyglyOEt, gly-cleuOEt; 2 L = metOEt) have been obtained by oxidative addition of halogenes to platinum(II) compounds PtX2L2A high field shift of <3N (—50 ppm) is observed for the coordinated amino acid ligand of various platinum c...

OBJECTIVE Primary platinum-resistant epithelial ovarian cancer (EOC) is an area of unmet medical need. There is limited evidence from small studies that platinum-based combinations can overcome "resistance" in a proportion of patients. We investigated the efficacy and toxicity of platinum-based combination chemotherapy in the platinum-resistant and platinum-refractory setting. METHODS Epirubi...